CTA 056 |
Catalog No.GC50076 |
Le CTA 056 est un inhibiteur de l'ITK (IL-2-inducible T-cell kinase) avec une IC50 de 0,1 μM. CTA 056 cible sélectivement les lymphocytes T malins et module les oncomirs. Le CTA 056 induit l'apoptose et est un agent thérapeutique potentiel pour le traitement de la leucémie à cellules T et du lymphome.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1265822-30-7
Sample solution is provided at 25 µL, 10mM.
Interleukin-2-inducible T-cell kinase (ITK) inhibitor (IC50 values are 0.1, 0.4 and 5 μM for ITK, BTK and ETK, respectively). Inhibits growth of cancer cells expressing ITK, including MOLT-4 and Jurkat cells in vitro. Induces apoptosis in Jurkat cells. Inhibits MOLT-4 xenograft tumor growth in mice.
Guo et al (2012) Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol.Pharmacol. 82 938 PMID:22899868
Average Rating: 5
(Based on Reviews and 15 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *